Clinical Research

Apellis Pharmaceuticals Inc.

Address
100 5th Avenue

Sponsor Overview

assignment
6
sponsored trials
science
32
molecules
location_city
81
research centres
public
11
countries
person_search
93
investigators

Specializations

C3 glomerulopathy and immune complex membranoproliferative glomerulonephritis

Clinical research in complement-mediated kidney disease centers on C3 glomerulopathy and IC-MPGN, with attention to renal inflammation, proteinuria, and disease recurrence after transplantation.

  • C3 glomerulopathy
  • immune complex membranoproliferative glomerulonephritis
  • proteinuria
  • post-transplant recurrence

These studies reflect a strong interest in renal disorders driven by dysregulation of the complement system.

Paroxysmal nocturnal hemoglobinuria

Research in paroxysmal nocturnal hemoglobinuria focuses on a rare hematologic disorder marked by complement-driven hemolysis and related blood abnormalities, with particular attention to adolescent patients.

  • paroxysmal nocturnal hemoglobinuria
  • hemolysis
  • hematologic disease
  • adolescent care

The clinical program extends the sponsor’s interest in rare diseases linked to complement inhibition.

Geographic atrophy secondary to age-related macular degeneration

Ophthalmic research addresses geographic atrophy associated with age-related macular degeneration, a progressive retinal condition that affects central vision and retinal integrity.

  • geographic atrophy
  • age-related macular degeneration
  • retinal disease
  • vision loss

This area highlights therapeutic interest in ophthalmology and degenerative retinal disease.

Complement pathway modulation

Across its studies, the sponsor focuses on diseases rooted in alternative complement pathway overactivity, linking kidney, blood, and eye disorders through a shared biological mechanism.

  • complement pathway
  • alternative complement pathway
  • rare disease therapeutics
  • renal, hematologic, and ophthalmic disorders

Its research portfolio spans multiple clinical areas where complement dysregulation is central to disease activity.

Sponsored Trials

Trial Name Country Status
Evaluation of Long-term Safety and Efficacy of Pegcetacoplan in Patients with C3 Glomerulopathy or Immune-Complex Membranoproliferative GlomerulonephritisAustria AustriaBelgium BelgiumCzechia CzechiaFrance FranceGermany GermanyItaly ItalySpain SpainThe Netherlands The NetherlandsNot Recruiting
Evaluation of Pegcetacoplan for Reducing Proteinuria in Adults and Adolescents with Focal Segmental GlomerulosclerosisFrance FranceGermany GermanyItaly ItalyPoland PolandPortugal PortugalSlovakia SlovakiaSpain SpainNot Yet Recruiting
Evaluation of Pegcetacoplan for Safety and Efficacy in Post-Transplant Recurrence of Complement 3 Glomerulopathy or Immune Complex Membranoproliferative GlomerulonephritisAustria AustriaItaly ItalyThe Netherlands The NetherlandsNot Recruiting
Evaluation of Safety, Pharmacokinetics, and Biologic Activity of Pegcetacoplan in Adolescents with Paroxysmal Nocturnal Hemoglobinuria: A Phase 2, Open-Label, Single-Arm StudySpain SpainThe Netherlands The NetherlandsRecruiting
Long-Term Safety and Efficacy Evaluation of Intravitreal Pegcetacoplan in Geographic Atrophy Secondary to Age-Related Macular DegenerationCzechia CzechiaFrance FranceGermany GermanyItaly ItalyPoland PolandSpain SpainThe Netherlands The NetherlandsNot Recruiting
Phase 3 Randomized Double-Blind Placebo-Controlled Study of Pegcetacoplan in C3 Glomerulopathy and Immune-Complex Membranoproliferative GlomerulonephritisAustria AustriaGermany GermanyItaly ItalyThe Netherlands The NetherlandsNot Recruiting

Data & Insights

science
Molecule Portfolio
Compounds under investigation
0
Exclusive Molecules
out of 32 total (0% not shared with other sponsors)

This sponsor works with 32 molecules, of which 0 are not being studied by other sponsors.

hub
Site Partnerships
Collaboration with research centres
20%
Return partnership rate
16 of 81 sites collaborated multiple times

This sponsor has worked with 81 sites across their trial portfolio.

Therapeutic Focus

  • 1.
    Immune System Diseases3 trials
    322 other sponsors
  • 2.
    Eye Diseases1 trial
    138 other sponsors
  • 3.
    Female Urogenital Diseases and Pregnancy Complications1 trial
    142 other sponsors
  • 4.
    Hemic and Lymphatic Diseases1 trial
    249 other sponsors
  • 5.
    Male Urogenital Diseases1 trial
    111 other sponsors

Partnered Research Centres

81 centres
location_city
assignment103
A.O.U. Policlinico G. Martino Di Messina
Address
Via Consolare Valeria N 1, 98124 Messina
Learn morearrow_forward
location_city
assignment680
Amsterdam UMC
Address
De Boelelaan 1117, 1081 HV Amsterdam
Learn morearrow_forward
location_city
assignment155
Amsterdam UMC
Address
Meibergdreef 9, 1105 AZ Amsterdam
Learn morearrow_forward
location_city
assignment966
Assistance Publique Hopitaux De Marseille
Address
264 Rue Saint Pierre, 13005 Marseille
Learn morearrow_forward
location_city
assignment153
ASST Fatebenefratelli Sacco
Address
Via Giovanni Battista Grassi 74, 20157 Milan
Learn morearrow_forward
location_city
assignment413
ASST Grande Ospedale Metropolitano Niguarda
Address
Piazza Dell'ospedale Maggiore 3, 20162 Milan
Learn morearrow_forward
Page 1 of 14

Want to get in touch with this sponsor?

Send a question and we'll pass it on to Apellis Pharmaceuticals Inc..

Need a custom report on this sponsor?

Competitive positioning, market entry, partnership opportunities — tell us the question.

Is something out of date?

Tell us what needs correcting and we'll update this profile.